Classification
Compound class	Synthetic organic
Approved drug?	Yes (FDA (2019))

International Nonproprietary Names
INN number	INN
10209	upadacitinib

Synonyms

ABT-494 | Rinvoq®

Comments

Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity [5,10]. The chemical structure is claimed as compound 1 in Abbvie's patent WO2015061665 [10]. It was developed for potential clinical efficacy in multiple autoimmune diseases. Its first approval was for the treatment of rheumatoid arthritis [2].

Database Links
GtoPdb PubChem SID	315661321
PubChem CID	58557659
Search Google for chemical match using the InChIKey	WYQFJHHDOKWSHR-MNOVXSKESA-N
Search Google for chemicals with the same backbone	WYQFJHHDOKWSHR
Search PubMed clinical trials	upadacitinib
Search PubMed titles	upadacitinib
Search PubMed titles/abstracts	upadacitinib
Search UniChem for chemical match using the InChIKey	WYQFJHHDOKWSHR-MNOVXSKESA-N
Search UniChem for chemicals with the same backbone	WYQFJHHDOKWSHR